Skip to main content
SpringerLink
Log in
Book cover

Contraception and Pregnancy in Patients with Rheumatic Disease pp 273–287Cite as

The Medical Management of the Rheumatology Patient During Pregnancy

  • Chapter
  • First Online:

  • 738 Accesses

Abstract

Decisions regarding medication use during pregnancy are amongst the most challenging clinicians will face. The health of both the mother and the developing fetus must be taken into account when designing a treatment plan. Limited data on an individual drug’s risk for use during pregnancy and conflicting recommendations regarding drug safety contribute to uncertainty in therapy choices. Clinicians and patients individually have their own risk tolerance for prescribing and taking medications. Finally, pregnancy itself can impact an individual patient’s disease activity rendering typical treatment approaches invalid. This chapter will discuss the treatment of the pregnant and nursing woman with a rheumatic disease. It will review the literature on commonly used medications for rheumatic disease management including aspirin, the nonsteroidal anti-inflammatory medications and COX-2 inhibitors; the glucocorticoids; the antimalarials; sulfasalazine; the immunosuppressive agents azathioprine and 6-mercaptopurine, cyclosporine, mycophenolate mofetil, and tacrolimus; the anti-metabolite methotrexate; leflunomide; cylophosphamide; intravenous immunoglobulin; the biologics including tumor necrosis factor-α (TNF-α) blockers, rituximab, belimumab, actemra, anakinra, abatacept, and tocilizumab; the anti-coagulants warfarin and unfractionated and fractionated heparin and colchicine. Wherever possible, specific recommendations will be made.

An erratum to this chapter is available at http://dx.doi.org/10.1007/978-1-4939-0673-4_16

An erratum to this chapter can be found at http://dx.doi.org/10.1007/978-1-4939-0673-4_16

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Kalter H, Warkany J. Congenital malformations (second of two parts). N Engl J Med. 1983;308(9):491–7.

    Article  PubMed  CAS  Google Scholar 

  2. Briggs GG. Preface. In: Briggs GGF, Roger K, Yaffe SJ, editors. Drugs in pregnancy and lactation. 9th ed. Philadelphia: Lippincott Williams &Wilkins; 2011. p. ix.

    Google Scholar 

  3. Bramham K, Soh MC, Nelson-Piercy C. Pregnancy and renal outcomes in lupus nephritis: an update and guide to management. Lupus. 2012;21(12):1271–83.

    Article  PubMed  CAS  Google Scholar 

  4. Warkary J, Takacs E. Experimental production of congenital malformations in rats by salicylate poisoning. Am J Pathol. 1959;35:924–36.

    Google Scholar 

  5. Kozer E, Nikfar S, Costei A, Boskovic R, Nulman I, Koren G. Aspirin consumption during the first trimester of pregnancy and congenital anomalies: a meta-analysis. Am J Obstet Gynecol. 2002;187(6):1623–30.

    Article  PubMed  Google Scholar 

  6. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of pre-eclampsia: a meta-analysis of individual patient data. Lancet. 2007;369(9575):1791–8.

    Article  PubMed  CAS  Google Scholar 

  7. Schoenfeld A, Bar Y, Merlob P, Ovadia Y. NSAIDs: maternal and fetal considerations. Am J Reprod Immunol. 1992;28(3–4):141–7.

    Article  PubMed  CAS  Google Scholar 

  8. Koren G, Florescu A, Costei AM, Boskovic R, Moretti ME. Nonsteroidal antiinflammatory drugs during third trimester and the risk of premature closure of the ductus arteriosus: a meta-analysis. Ann Pharmacother. 2006;40(5):824–9.

    Article  PubMed  CAS  Google Scholar 

  9. Nakhai-Pour HR, Broy P, Sheehy O, Berard A. Use of nonaspirin nonsteroidal anti-inflammatory drugs during pregnancy and the risk of spontaneous abortion. CMAJ. 2011;183(15):1713–20.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Edwards DR, Aldridge T, Baird DD, Funk MJ, Savitz DA, Hartmann KE. Periconceptional over-the-counter nonsteroidal anti-inflammatory drug exposure and risk for spontaneous abortion. Obstet Gynecol. 2012;120(1):113–22.

    Article  PubMed  CAS  Google Scholar 

  11. Mendonca LL, Khamashta MA, Nelson-Piercy C, Hunt BJ, Hughes GR. Non-steroidal anti-inflammatory drugs as a possible cause for reversible infertility. Rheumatology (Oxford). 2000;39(8):880–2.

    Article  CAS  Google Scholar 

  12. Uhler ML, Hsu JW, Fisher SG, Zinaman MJ. The effect of nonsteroidal anti-inflammatory drugs on ovulation: a prospective, randomized clinical trial. Fertil Steril. 2001;76(5):957–61.

    Article  PubMed  CAS  Google Scholar 

  13. American Academy of Pediatrics Committee on Drugs. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108(3):776–89.

    Google Scholar 

  14. Blanford AT, Murphy BE. In vitro metabolism of prednisolone, dexamethasone, betamethasone, and cortisol by the human placenta. Am J Obstet Gynecol. 1977;127(3):264–7.

    PubMed  CAS  Google Scholar 

  15. Jobe AH, Soll RF. Choice and dose of corticosteroid for antenatal treatments. Am J Obstet Gynecol. 2004;190(4):878–81.

    Article  PubMed  CAS  Google Scholar 

  16. Reinisch JM, Simon NG, Gandelman R. Prenatal exposure to prednisone permanently alters fighting behavior of female mice. Pharmacol Biochem Behav. 1980;12(2):213–6.

    Article  PubMed  CAS  Google Scholar 

  17. Pinsky L, Digeorge AM. Cleft palate in the mouse: a teratogenic index of glucocorticoid potency. Science. 1965;147(3656):402–3.

    Article  PubMed  CAS  Google Scholar 

  18. Schatz M, Patterson R, Zeitz S, O'Rourke J, Melam H. Corticosteroid therapy for the pregnant asthmatic patient. JAMA. 1975;233(7):804–7.

    Article  PubMed  CAS  Google Scholar 

  19. Park-Wyllie L, Mazzotta P, Pastuszak A, Moretti ME, Beique L, Hunnisett L, et al. Birth defects after maternal exposure to corticosteroids: prospective cohort study and meta-analysis of epidemiological studies. Teratology. 2000;62(6):385–92.

    Article  PubMed  CAS  Google Scholar 

  20. Bay Bjorn AM, Ehrenstein V, Holmager Hundborg H, Aagaard Nohr E, Toft Sorensen H, Norgaard M. Use of corticosteroids in early pregnancy is not associated with risk of oral clefts and other congenital malformations in offspring. Am J Ther. 2012;21(2):73–80.

    Article  Google Scholar 

  21. Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106(6):1008–11.

    Article  PubMed  CAS  Google Scholar 

  22. Ullberg S, Lindquist NG, Sjostrand SE. Accumulation of chorio-retinotoxic drugs in the foetal eye. Nature. 1970;227(5264):1257–8.

    Article  PubMed  CAS  Google Scholar 

  23. Hart CW, Naunton RF. The ototoxicity of chloroquine phosphate. Arch Otolaryngol. 1964;80:407–12.

    Article  PubMed  CAS  Google Scholar 

  24. Costedoat-Chalumeau N, Amoura Z, Huong DL, Lechat P, Piette JC. Safety of hydroxychloroquine in pregnant patients with connective tissue diseases. Review of the literature. Autoimmun Rev. 2005;4(2):111–5.

    Article  PubMed  CAS  Google Scholar 

  25. Motta M, Tincani A, Faden D, Zinzini E, Lojacono A, Marchesi A, et al. Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. J Perinatol. 2005;25(2):86–9.

    Article  PubMed  CAS  Google Scholar 

  26. Al-Herz A, Schulzer M, Esdaile JM. Survey of antimalarial use in lupus pregnancy and lactation. J Rheumatol. 2002;29(4):700–6.

    PubMed  Google Scholar 

  27. Clowse ME, Magder L, Witter F, Petri M. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum. 2006;54(11):3640–7.

    Article  PubMed  Google Scholar 

  28. Tunks RD, Clowse ME, Miller SG, Brancazio LR, Barker PC. Maternal autoantibody levels in congenital heart block and potential prophylaxis with antiinflammatory agents. Am J Obstet Gynecol. 2013;208(1):64 e1–7.

    Google Scholar 

  29. Mogadam M, Dobbins 3rd WO, Korelitz BI, Ahmed SW. Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology. 1981;80(1):72–6.

    PubMed  CAS  Google Scholar 

  30. Rahimi R, Nikfar S, Rezaie A, Abdollahi M. Pregnancy outcome in women with inflammatory bowel disease following exposure to 5-aminosalicylic acid drugs: a meta-analysis. Reprod Toxicol. 2008;25(2):271–5.

    Article  PubMed  CAS  Google Scholar 

  31. Hernandez-Diaz S, Werler MM, Walker AM, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med. 2000;343(22):1608–14.

    Article  PubMed  CAS  Google Scholar 

  32. Gross A, Fein A, Serr DM, Nebel L. The effect of Imuran on implantation and early embryonic development in rats. Obstet Gynecol. 1977;50(6):713–8.

    PubMed  CAS  Google Scholar 

  33. Saarikoski S, Seppala M. Immunosuppression during pregnancy: transmission of azathioprine and its metabolites from the mother to the fetus. Am J Obstet Gynecol. 1973;115(8):1100–6.

    PubMed  CAS  Google Scholar 

  34. Alstead EM, Ritchie JK, Lennard-Jones JE, Farthing MJ, Clark ML. Safety of azathioprine in pregnancy in inflammatory bowel disease. Gastroenterology. 1990;99(2):443–6.

    PubMed  CAS  Google Scholar 

  35. Armenti VT, Ahlswede KM, Ahlswede BA, Cater JR, Moritz MJ, Burke JF. National Transplantation Pregnancy Registry: analysis of outcome/risks of 394 pregnancies in kidney transplant recipients. Transplant Proc. 1994;26(5):2535.

    PubMed  CAS  Google Scholar 

  36. Akbari M, Shah S, Velayos FS, Mahadevan U, Cheifetz AS. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(1):15–22.

    Article  PubMed  Google Scholar 

  37. Mahadevan U, Kane S. American gastroenterological association institute medical position statement on the use of gastrointestinal medications in pregnancy. Gastroenterology. 2006;131(1):278–82.

    Article  PubMed  Google Scholar 

  38. Mason RJ, Thomson AW, Whiting PH, Gray ES, Brown PA, Catto GR, et al. Cyclosporine-induced fetotoxicity in the rat. Transplantation. 1985;39(1):9–12.

    PubMed  CAS  Google Scholar 

  39. al-Khader AA, Absy M, al-Hasani MK, Joyce B, Sabbagh T. Successful pregnancy in renal transplant recipients treated with cyclosporine. Transplantation. 1988;45(5):987–8.

    Article  PubMed  CAS  Google Scholar 

  40. Nandakumaran M, Eldeen AS. Transfer of cyclosporine in the perfused human placenta. Dev Pharmacol Ther. 1990;15(2):101–5.

    PubMed  CAS  Google Scholar 

  41. Bar Oz B, Hackman R, Einarson T, Koren G. Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation. 2001;71(8):1051–5.

    Article  PubMed  CAS  Google Scholar 

  42. Nyberg G, Haljamae U, Frisenette-Fich C, Wennergren M, Kjellmer I. Breast-feeding during treatment with cyclosporine. Transplantation. 1998;65(2):253–5.

    Article  PubMed  CAS  Google Scholar 

  43. Henderson LK, Masson P, Craig JC, Roberts MA, Flanc RS, Strippoli GF, et al. Induction and maintenance treatment of proliferative lupus nephritis: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2013;61(1):74–87.

    Article  PubMed  Google Scholar 

  44. Sifontis NM, Coscia LA, Constantinescu S, Lavelanet AF, Moritz MJ, Armenti VT. Pregnancy outcomes in solid organ transplant recipients with exposure to mycophenolate mofetil or sirolimus. Transplantation. 2006;82(12):1698–702.

    Article  PubMed  CAS  Google Scholar 

  45. Perez-Aytes A, Ledo A, Boso V, Saenz P, Roma E, Poveda JL, et al. In utero exposure to mycophenolate mofetil: a characteristic phenotype? Am J Med Genet A. 2008;146A(1):1–7.

    Article  PubMed  Google Scholar 

  46. Deng J, Huo D, Wu Q, Yang Z, Liao Y. A meta-analysis of randomized controlled trials comparing tacrolimus with intravenous cyclophosphamide in the induction treatment for lupus nephritis. Tohoku J Exp Med. 2012;227(4):281–8.

    Article  PubMed  CAS  Google Scholar 

  47. Kainz A, Harabacz I, Cowlrick IS, Gadgil SD, Hagiwara D. Review of the course and outcome of 100 pregnancies in 84 women treated with tacrolimus. Transplantation. 2000;70(12):1718–21.

    Article  PubMed  CAS  Google Scholar 

  48. Jain A, Venkataramanan R, Fung JJ, Gartner JC, Lever J, Balan V, et al. Pregnancy after liver transplantation under tacrolimus. Transplantation. 1997;64(4):559–65.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  49. Bramham K, Chusney G, Lee J, Lightstone L, Nelson-Piercy C. Breastfeeding and tacrolimus: serial monitoring in breast-fed and bottle-fed infants. Clin J Am Soc Nephrol. 2013;8(4): 563–7.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  50. Pincus T, O’Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. Ann Intern Med. 1999;131(10): 768–74.

    Article  PubMed  CAS  Google Scholar 

  51. Hoppe DE, Bekkar BE, Nager CW. Single-dose systemic methotrexate for the treatment of persistent ectopic pregnancy after conservative surgery. Obstet Gynecol. 1994;83(1):51–4.

    PubMed  CAS  Google Scholar 

  52. Wilson JG, Scott WJ, Ritter EJ, Fradkin R. Comparative distribution and embryotoxicity of methotrexate in pregnant rats and rhesus monkeys. Teratology. 1979;19(1):71–9.

    Article  PubMed  Google Scholar 

  53. Lecuru F, Querleu D, Buchet-Bouverne B, Subtil D. The effect of tubal injection of methotrexate on fertility in the rabbit. Fertil Steril. 1992;57(2):422–4.

    PubMed  CAS  Google Scholar 

  54. Bawle EV, Conard JV, Weiss L. Adult and two children with fetal methotrexate syndrome. Teratology. 1998;57(2):51–5.

    Article  PubMed  CAS  Google Scholar 

  55. Feldkamp M, Carey JC. Clinical teratology counseling and consultation case report: low dose methotrexate exposure in the early weeks of pregnancy. Teratology. 1993;47(6):533–9.

    Article  PubMed  CAS  Google Scholar 

  56. Lloyd ME, Carr M, McElhatton P, Hall GM, Hughes RA. The effects of methotrexate on pregnancy, fertility and lactation. QJM. 1999;92(10):551–63.

    Article  PubMed  CAS  Google Scholar 

  57. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. Methotrexate exposure prior to and during pregnancy. Teratology. 1994;49(2):79–81.

    Article  PubMed  CAS  Google Scholar 

  58. Fukushima R, Kanamori S, Hirashiba M, Hishikawa A, Muranaka RI, Kaneto M, et al. Teratogenicity study of the dihydroorotate-dehydrogenase inhibitor and protein tyrosine kinase inhibitor Leflunomide in mice. Reprod Toxicol. 2007;24(3–4):310–6.

    Article  PubMed  CAS  Google Scholar 

  59. Neville CE, McNally J. Maternal exposure to leflunomide associated with blindness and cerebral palsy. Rheumatology (Oxford). 2007;46(9):1506.

    Article  CAS  Google Scholar 

  60. Cassina M, Johnson DL, Robinson LK, Braddock SR, Xu R, Jimenez JL, et al. Pregnancy outcome in women exposed to leflunomide before or during pregnancy. Arthritis Rheum. 2012;64(7):2085–94.

    Article  PubMed  CAS  Google Scholar 

  61. Hsu HC, Tsai HM. Cyclophosphamide-induced glomerular injury in newborn mice. Lab Invest. 1982;47(3):281–5.

    PubMed  CAS  Google Scholar 

  62. Greenberg LH, Tanaka KR. Congenital Anomalies Probably Induced by Cyclophosphamide. JAMA. 1964;188:423–6.

    Article  PubMed  CAS  Google Scholar 

  63. Fields CL, Ossorio MA, Roy TM, Bunke CM. Wegener’s granulomatosis complicated by pregnancy. A case report. J Reprod Med. 1991;36(6):463–6.

    PubMed  CAS  Google Scholar 

  64. Hardin JA. Cyclophosphamide treatment of lymphoma during third trimester of pregnancy. Obstet Gynecol. 1972;39(6):850–1.

    PubMed  CAS  Google Scholar 

  65. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus. 1999;8(1):3–10.

    Article  PubMed  CAS  Google Scholar 

  66. Fabris P, Quaini R, Coser P, Casini M, Franceschini I, Pianezze G. Successful treatment of a steroid-resistant form of idiopathic thrombocytopenic purpura in pregnancy with high doses of intravenous immunoglobulins. Acta Haematol. 1987;77(2):107–10.

    Article  PubMed  CAS  Google Scholar 

  67. Parke A. The role of IVIG in the management of patients with antiphospholipid antibodies and recurrent pregnancy losses. Clin Rev Allergy. 1992;10(1–2):105–18.

    Google Scholar 

  68. Carter JD, Ladhani A, Ricca LR, Valeriano J, Vasey FB. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the Food and Drug Administration database. J Rheumatol. 2009;36(3):635–41.

    Article  PubMed  Google Scholar 

  69. Koren G, Inoue M. Do tumor necrosis factor inhibitors cause malformations in humans? J Rheumatol. 2009;36(3):465–6.

    Article  PubMed  Google Scholar 

  70. Crijns HJ, Jentink J, Garne E, Gispen-de Wied CC, Straus SM, de Jong-van den Berg LT. The distribution of congenital anomalies within the VACTERL association among tumor necrosis factor antagonist-exposed pregnancies is similar to the general population. J Rheumatol. 2011;38(9):1871–4.

    Article  PubMed  Google Scholar 

  71. Mahadevan U, Wolf DC, Dubinsky M, Cortot A, Lee SD, Siegel CA, et al. Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2013;11(3):286–92.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  72. Kimby E, Sverrisdottir A, Elinder G. Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol. 2004;72(4):292–5.

    Article  PubMed  Google Scholar 

  73. Herold M, Schnohr S, Bittrich H. Efficacy and safety of a combined rituximab chemotherapy during pregnancy. J Clin Oncol. 2001;19(14):3439.

    PubMed  CAS  Google Scholar 

  74. Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol. 2012;2012:985646.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Friedrichs B, Tiemann M, Salwender H, Verpoort K, Wenger MK, Schmitz N. The effects of rituximab treatment during pregnancy on a neonate. Haematologica. 2006;91(10):1426–7.

    PubMed  Google Scholar 

  76. Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med. 1980;68(1):122–40.

    Article  PubMed  CAS  Google Scholar 

  77. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med. 1989;149(10):2233–6.

    Article  PubMed  CAS  Google Scholar 

  78. Galambosi PJ, Kaaja RJ, Stefanovic V, Ulander VM. Safety of low-molecular-weight heparin during pregnancy: a retrospective controlled cohort study. Eur J Obstet Gynecol Reprod Biol. 2012;163(2):154–9.

    Article  PubMed  CAS  Google Scholar 

  79. Diav-Citrin O, Shechtman S, Schwartz V, Avgil-Tsadok M, Finkel-Pekarsky V, Wajnberg R, et al. Pregnancy outcome after in utero exposure to colchicine. Am J Obstet Gynecol. 2010;203(2):144 e1–6.

    Google Scholar 

  80. Ben-Chetrit E, Ben-Chetrit A, Berkun Y. Pregnancy outcomes in women with familial Mediterranean fever receiving colchicine: is amniocentesis justified? Arthritis Care Res (Hoboken). 2010;62(2):143–8.

    Article  Google Scholar 

  81. Chervenak F, McCullough LB. Responsibly counselling women about the clinical management of pregnancies complicated by severe fetal anomalies. J Med Ethics. 2012;38(7):397–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, 02115, MA, USA

    Bonnie L. Bermas M.D.

Authors
  1. Bonnie L. Bermas M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bonnie L. Bermas M.D. .

Editor information

Editors and Affiliations

  1. Division of Rheumatology, Hospital for Special Surgery Weill Cornell Medical College, New York, New York, USA

    Lisa R. Sammaritano

  2. Division of Rheumatology, Brigham and Women's Hospital, Boston, Massachusetts, USA

    Bonnie L. Bermas

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer Science+Business Media New York

About this chapter

Cite this chapter

Bermas, B.L. (2014). The Medical Management of the Rheumatology Patient During Pregnancy. In: Sammaritano, L., Bermas, B. (eds) Contraception and Pregnancy in Patients with Rheumatic Disease. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-0673-4_14

Download citation

  • DOI: https://doi.org/10.1007/978-1-4939-0673-4_14

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4939-0672-7

  • Online ISBN: 978-1-4939-0673-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation